Real-world evaluation of ceftolozane/tazobactam therapy and clinical outcomes in France
| Autor: | D. Boutoille, Carole Mackosso, Brune Akrich, Anna Amode, Bernard Castan, Joy Mootien, Raymond Ruimy, Fabrice Ruiz, Anne Berthelot, Lucie Mathis, Jean-François Timsit, Laurie Levy-Bachelot |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male Tazobactam medicine.medical_specialty medicine.drug_class Antibiotics Internal medicine Humans Medicine Pseudomonas Infections Prospective Studies Medical prescription Risk factor Prospective cohort study business.industry Middle Aged medicine.disease Cephalosporins Pneumonia Infectious Diseases Concomitant Pseudomonas aeruginosa Ceftolozane business medicine.drug |
| Zdroj: | Infectious Diseases Now. 51:532-539 |
| ISSN: | 2666-9919 |
| Popis: | Objectives To describe the real-world clinical use of ceftolozane/tazobactam (C/T) and associated outcomes in France. Patients and methods Multicenter, prospective cohort study conducted in 22 hospitals. All adult patients who received at least one dose of C/T were asked to participate (2018-2019). Patients were treated according to standard hospital practice and followed up until C/T stop. Results At the time of the analysis, 84 patients were evaluated. The median age was 64.8 years, and 67.9% (57/84) of patients were males. Fifty-seven patients (57/82, 69.5%) had one or more risk factors for multidrug-resistant (MDR) infections (missing MDR risk factor data for two patients). Most patients were critically ill and had several comorbidities. A majority (59/84, 70.2%) of patients had nosocomial infections. Half of all patients (n = 42) had a diagnosis of pneumonia, of which 69% (29/42) were hospital acquired. Overall, 90.5% (76/84) of patients had MDR bacteria. Pseudomonas aeruginosa was the most frequently isolated bacterium (71/80, 88.8%), including 93% (80/86) of C/T-susceptible strains. C/T was prescribed as the first-line treatment to 29.8% (25/84) of patients. A concomitant antibiotic treatment was prescribed to 48.8% (41/84) of patients, of whom 65.9% (27/41) were prescribed concomitant antibiotics at the same time as C/T initiation. Empirical C/T prescription was microbiologically appropriate in 11/16 patients after susceptibility testing. Most patients (44/72, 61.1%) were cured and four (4/72, 5.6%) deaths were reported. Conclusions The results showed that C/T was most frequently prescribed for documented cases of P. aeruginosa infections. Most outcomes were positive, including among pneumonia patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect